Banque Transatlantique Sa Argenx Se Call Options Transaction History
Banque Transatlantique Sa
- $5.69 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARGX
# of Institutions
497Shares Held
28.5MCall Options Held
330KPut Options Held
286K-
Price T Rowe Associates Inc Baltimore, MD5.38MShares$3.16 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.79MShares$1.64 Billion2.84% of portfolio
-
Janus Henderson Group PLC London, X02.14MShares$1.26 Billion0.73% of portfolio
-
Capital World Investors Los Angeles, CA1.94MShares$1.14 Billion0.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$726 Million11.83% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $32.5B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...